Puma and Xoma chase funds for late-stage projects, Orexigen raises cash for Contrave refiling
This article was originally published in Scrip
Executive Summary
Three companies that recently completed stock offerings to fund late-stage clinical trials and commercialisation activities have about as good a chance as their peers of winning US FDA approval, according to Sagient Research's BioMedTracker reports.